The stock of Lilly(Eli) & Co (LLY) has seen a -1.56% decrease in the past week, with a -1.16% drop in the past month, and a 17.47% flourish in the past quarter. The volatility ratio for the week is 2.41%, and the volatility levels for the past 30 days are at 2.19% for LLY. The simple moving average for the last 20 days is -2.97% for LLY’s stock, with a simple moving average of 22.21% for the last 200 days.
Is It Worth Investing in Lilly(Eli) & Co (NYSE: LLY) Right Now?
The price-to-earnings ratio for Lilly(Eli) & Co (NYSE: LLY) is above average at 131.13x, Company’s 36-month beta value is 0.38.Analysts have differing opinions on the stock, with 9 analysts rating it as a “buy,” 4 as “overweight,” 8 as “hold,” and 1 as “sell.”
The public float for LLY is 849.82M, and currently, short sellers hold a 0.64% ratio of that floaft. The average trading volume of LLY on April 16, 2024 was 3.06M shares.
LLY) stock’s latest price update
Lilly(Eli) & Co (NYSE: LLY)’s stock price has gone decline by -0.71 in comparison to its previous close of 750.77, however, the company has experienced a -1.56% decrease in its stock price over the last five trading days. Proactive Investors reported 2024-04-15 that Atossa Therapeutics Inc (NASDAQ:ATOS) and its research partner Quantum Leap Healthcare Collaborative announced the initiation of a new study evaluating Atossa’s lead drug candidate (Z)-endoxifen in combination with Eli Lilly and Co (NYSE:LLY)’s abemaciclib (VERZENIO) in women with Estrogen Receptor positive (ER+)/Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. The clinical-stage biopharmaceutical company said the new study arm would enroll approximately 20 women newly diagnosed with ER+/HER2- invasive breast cancer.
Analysts’ Opinion of LLY
Many brokerage firms have already submitted their reports for LLY stocks, with DZ Bank repeating the rating for LLY by listing it as a “Hold.” The predicted price for LLY in the upcoming period, according to DZ Bank is $820 based on the research report published on February 21, 2024 of the current year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see LLY reach a price target of $950, previously predicting the price at $805. The rating they have provided for LLY stocks is “Overweight” according to the report published on February 16th, 2024.
Daiwa Securities gave a rating of “Outperform” to LLY, setting the target price at $610 in the report published on December 21st of the previous year.
LLY Trading at -1.78% from the 50-Day Moving Average
After a stumble in the market that brought LLY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.91% of loss for the given period.
Volatility was left at 2.19%, however, over the last 30 days, the volatility rate increased by 2.41%, as shares sank -1.78% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +12.20% upper at present.
During the last 5 trading sessions, LLY fell by -1.08%, which changed the moving average for the period of 200-days by +61.27% in comparison to the 20-day moving average, which settled at $767.55. In addition, Lilly(Eli) & Co saw 27.88% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LLY starting from Zakrowski Donald A, who sale 750 shares at the price of $753.60 back on Mar 11 ’24. After this action, Zakrowski Donald A now owns 7,880 shares of Lilly(Eli) & Co, valued at $565,200 using the latest closing price.
LILLY ENDOWMENT INC, the 10% Owner of Lilly(Eli) & Co, sale 169,684 shares at $780.99 during a trade that took place back on Feb 16 ’24, which means that LILLY ENDOWMENT INC is holding 98,898,810 shares at $132,521,930 based on the most recent closing price.
Stock Fundamentals for LLY
Current profitability levels for the company are sitting at:
- 0.21 for the present operating margin
- 0.8 for the gross margin
The net margin for Lilly(Eli) & Co stands at 0.15. The total capital return value is set at 0.19. Equity return is now at value 48.93, with 9.23 for asset returns.
Based on Lilly(Eli) & Co (LLY), the company’s capital structure generated 0.7 points at debt to capital in total, while cash flow to debt ratio is standing at 0.17. The debt to equity ratio resting at 2.34. The interest coverage ratio of the stock is 16.19.
Currently, EBITDA for the company is 12.46 billion with net debt to EBITDA at 1.6. When we switch over and look at the enterprise to sales, we see a ratio of 21.43. The receivables turnover for the company is 3.01for trailing twelve months and the total asset turnover is 0.53. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.94.
Conclusion
In a nutshell, Lilly(Eli) & Co (LLY) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
